- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Proliferative diabetic retinopathy (PDR)
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Ranibizumab – May 2025
Ranibizumab: Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, Solution for intravitreal injection 2.3 mg in 0.23 mL; Lucentis®
Last updated
9 May 2025